share_log

CVS Health | 424B2: Prospectus

CVS Health | 424B2: Prospectus

西维斯健康 | 424B2:募资说明书
美股SEC公告 ·  12/06 05:09

Moomoo AI 已提取核心信息

On December 3, 2024, CVS Health announced the offering of $3 billion in junior subordinated notes, comprising $2.25 billion of 7.000% Series A notes due 2055 and $750 million of 6.750% Series B notes due 2054. The Series A notes will bear interest at 7.000% until March 10, 2030, and the Series B notes at 6.750% until December 10, 2034, with rates resetting based on the Five-year U.S. Treasury Rate plus a spread.The proceeds will be used for tender offers to repurchase existing senior notes, including those due in 2025 and 2040, and for general corporate purposes. The notes are unsecured and subordinated, ranking junior to existing senior debt. Interest payments can be deferred for up to 10 years.The offering is not contingent on the completion of the tender offers. The notes will not be listed on any securities exchange, and the offering is expected to close on December 10, 2024.
On December 3, 2024, CVS Health announced the offering of $3 billion in junior subordinated notes, comprising $2.25 billion of 7.000% Series A notes due 2055 and $750 million of 6.750% Series B notes due 2054. The Series A notes will bear interest at 7.000% until March 10, 2030, and the Series B notes at 6.750% until December 10, 2034, with rates resetting based on the Five-year U.S. Treasury Rate plus a spread.The proceeds will be used for tender offers to repurchase existing senior notes, including those due in 2025 and 2040, and for general corporate purposes. The notes are unsecured and subordinated, ranking junior to existing senior debt. Interest payments can be deferred for up to 10 years.The offering is not contingent on the completion of the tender offers. The notes will not be listed on any securities exchange, and the offering is expected to close on December 10, 2024.
2024年12月3日,CVS Health宣布发行30亿美元的初级次级次级票据,包括2055年到期的22.5亿美元7.000%的A系列票据和2054年到期的7.5亿美元6.750%的b系列票据。在2030年3月10日之前,A系列票据的利息将为7.000%,在2034年12月10日之前,b系列票据的利息为6.750%,利率将根据五年期美国国债利率加利差进行重置。所得款项将用于要约回购现有优先票据,包括2025年和2040年到期的优先票据,并用于一般公司用途。这些票据是无抵押的,是次要债券,排名低于现有的优先债务。利息支付最多可以延期10年。此次发行不以投标要约的完成为条件。这些票据不会在任何证券交易所上市,发行预计将于2024年12月10日结束。
2024年12月3日,CVS Health宣布发行30亿美元的初级次级次级票据,包括2055年到期的22.5亿美元7.000%的A系列票据和2054年到期的7.5亿美元6.750%的b系列票据。在2030年3月10日之前,A系列票据的利息将为7.000%,在2034年12月10日之前,b系列票据的利息为6.750%,利率将根据五年期美国国债利率加利差进行重置。所得款项将用于要约回购现有优先票据,包括2025年和2040年到期的优先票据,并用于一般公司用途。这些票据是无抵押的,是次要债券,排名低于现有的优先债务。利息支付最多可以延期10年。此次发行不以投标要约的完成为条件。这些票据不会在任何证券交易所上市,发行预计将于2024年12月10日结束。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息